January 27, 2022 -- Purigen Biosystems entered a new distribution agreement with the Institute of Applied Biotechnologies (IAB). Under the agreement, IAB has received exclusive rights to distribute, service, and support Purigen's automated ionic purification system and microfluidic kits in the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Clinical and oncology researchers in select European Union (EU) countries are now able to purchase and use the benchtop system, which received a CE Mark in May 2021, to extract higher yields of purified DNA and RNA from challenging samples.
The small benchtop ionic purification system enables a wide range of sample types, including cultured or sorted cells and formalin-fixed, paraffin-embedded tissues. The system applies an electrical field to the chip, and the nucleic acids are isolated in their native form using the company's core isotachophoresis technology, Purigen said. The simplified workflow requires minimal hands-on time and ensures that sufficient amounts of nucleic acid are available for all downstream analysis techniques, such as next-generation sequencing and quantitative PCR (qPCR), according to Purigen.
IAB offers advanced end-to-end polymerase chain reaction PCR, qPCR, optical genome mapping, and next-generation solutions for customers across the EU.
Financial terms of the agreement were not disclosed.